arrow
D

Daniel Kazdal

national center for tumor diseases
H指数:31
被引数:3,224

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Spatially Fractionated Induction Radiotherapy to Widen the Therapeutic Window in Locally Advanced Non-Small-Cell Lung Cancer (SPARROW): Study Protocol of a Multicenter, Randomized, Open-Label Seamless Phase I/II Trial

空间分割诱导放射治疗以扩大局部晚期非小细胞肺癌的治疗窗口(SPARROW):一项多中心、随机、开放标签无缝式I/II期试验研究方案

2026-08-010
PRE
Comprehensive Liquid Biopsy Testing in Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer Patients: First Results from Routine Clinical Practice

转移性激素受体阳性HER2阴性乳腺癌患者中的全面液体活检检测:来自常规临床实践的首批结果

2026-05-010
PRE
Differential KEAP1/NRF2 mediated signaling widens the therapeutic window of redox-targeting drugs in SCLC therapy

差异性的KEAP1/NRF2介导的信号传导拓宽了氧化还原靶向药物在小细胞肺癌治疗中的治疗窗口

2026-04-120
OAAI
Implementing whole genome and transcriptome sequencing for cancer patients in routine healthcare: a comprehensive guide to costing

在常规医疗保健中为癌症患者实施全基因组与转录组测序:成本核算的全面指南

2026-04-070
OAAI
Correction: Diagnostic whole transcriptome sequencing in a series of 1233 FFPE solid tumor samples

更正:对1233例FFPE实体瘤样本进行诊断性全转录组测序

2026-03-020
OAAI
Diagnostic whole transcriptome sequencing in a series of 1233 FFPE solid tumor samples

在1233例FFPE实体瘤样本中进行的诊断性全转录组测序

2026-01-140
OAAI
Costs of biomarker testing in advanced non-small cell lung cancer: a global study comparing next-generation sequencing and single-gene testing
2025-03-011
OAAI
Biopsy-derived organoids in personalised early breast cancer care: Challenges of tumour purity and normal cell overgrowth cap their practical utility
2025-02-010
OAAI
Clinical Implementation of a High-Throughput Automated Comprehensive Genomic Profiling Test TruSight Oncology 500 HT
2025-02-010
OAAI
First-line immunotherapy for lung cancer with MET exon 14 skipping and the relevance of TP53 mutations (vol 199, 113556, 2024)
2024-07-010
PRE